Vertex Pharma (VRTX) Reports In-Line Q3 EPS; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $553.15 -1.03%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.76, in-line with the analyst estimate of $4.76. Revenue for the quarter came in at $3.44 billion versus the consensus estimate of $3.41 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $13.15-13.25 billion, versus the consensus of $13.281 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Offerpad Solutions Inc. (OPAD) Misses Q3 EPS by 72c
- National Presto Indust. (NPK) Reports Q3 EPS of $2.79
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
